file photo

file photo

Clinical trial to begin for new Alzheimer’s disease treatment

Activation of signaling pathway is expected to regenerate neural cells.

A clinical trial of a new potential Alzheimer’s disease treatment at Northwest Clinical Research Center in Bellevue raises hopes of a therapeutic treatment for a disease that was the third-largest cause of death in the state during 2019.

According to the Alzheimer’s Association, there are over 120,000 Washingtonians living with Alzheimer’s disease as of last year.

A principal investigator of the clinical study, Dr. Arif Khan, said while it is not totally understood what causes Alzheimer’s, it happens when neural cells in the brain degenerate, entangle and receive protein deposits that affect their “connectivity,” to one another.

This causes a loss in cognitive function, irritability, mood swings, inability to sleep, paranoia and most notably, memory loss.

Khan said neuronal degeneration has been associated with aging since the 1970’s and can become fatal quickly as the disease progresses to more severe stages.

Khan said previously tested treatments have been generally ineffective. He said 50 years ago, researchers tried a treatment that made dopamine more available in the brain as a way to mitigate Alzheimer’s disease. He said this treatment was more-so a “band-aid,” solution.

He said 20 years ago researchers tried using monoclonal antibodies to absorb the protein deposits in the brain that obstructed the connectivity of neural cells.

The trial, conducted by Khan as well as other physicians throughout the U.S. will test a new treatment that he said activates a naturally-occurring pathway, called HGF/MET, to help the broken down neural cells regenerate and in-turn improve cognitive function.

Khan said the the small molecule that activates this pathway, known as ATH-1017, is expected to make neural cells more “young and active,” at least that is the theory behind the clinical trial.

The treatment will be administered with daily injections into patients. Khan compared the treatment to a small needle shot.

He also emphasized that the trial will include patients with mild to moderate Alzheimer’s disease. If the data from this study are positive, ATH-1017 could be studied in both more severe and earlier-stage Alzheimer’s patients.

Spokesperson for Athira Pharma, Maggie Beller, said the trial will include up to 300 participants, with two-thirds of them receiving the daily treatment and the other third receiving a placebo over six months.

For more information, visit https://www.athiraclinicaltrials.com/ or call 1-800-668-4717.


In consideration of how we voice our opinions in the modern world, we’ve closed comments on our websites. We value the opinions of our readers and we encourage you to keep the conversation going.

Please feel free to share your story tips by emailing editor@bellevuereporter.com.

To share your opinion for publication, submit a letter through our website https://www.bellevuereporter.com/submit-letter/. Include your name, address and daytime phone number. (We’ll only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 300 words or less, we won’t ask you to shorten it.

More in News

(Pixabay.com)
As rates of stoned drivers increase, law enforcement face challenges

WSP trooper said a THC breathalyzer would be a “game changer” for law enforcement and courts.

E. coli. Photo courtesy of the Food and Drug Administration
Seven King County children sickened with E. coli

Seven children in King County have been infected with E. coli, a… Continue reading

Sound Publishing file photo
Remi Frederick, a Village Green employee, receives her first dose of the Pfizer-BioNTech vaccine on Jan. 26 in Federal Way.
County health officer looks to community immunity instead of herd immunity

Herd immunity may be unlikely to reach King County anytime soon, but… Continue reading

t
Bellevue hoops teams conclude seasons

Left, Bellevue’s Ryan Brush takes a shot during a matchup against Interlake… Continue reading

Governor Jay Inslee. Sound Publishing file photo
New laws will tax the rich, offer aid to low-income workers

Inslee signs bill creating capital gains tax; foes are challenging it in court as unconstitutional.

Washington state case count since March 2020. WA Governor's Office
Pandemic pause: King County remains in Phase 3

No Washington state counties will be rolling back their phase under the… Continue reading

Courtesy of Washington Military Department
Washington gets mobile earthquake alerts

Washington state will have its own earthquake early warning system on May… Continue reading

Protesters hold a sign near PSE Mary Kipp’s house (photo credit: Neal Anderson)
Indigenous leaders and kayaktivists protest in front of the home of Puget Sound Energy CEO

Multiple groups gathered in opposition to the Tacoma LNG facility.

Photo via Pexels
King County residents needed for first respiratory study using Apple watches

UW study to help find if devices can detect early warning signs of acute respiratory infections, such as COVID-19 and flu.

Most Read